Latest PERCEPTIVE ADVISORS LLC Stock Portfolio
$5.12Billion– No. of Holdings #91
Joseph Edelman Performance:
2026 Q1: 4.73%YTD: 4.73%2025: 57.06%
Performance for 2026 Q1 is 4.73%, and YTD is 4.73%, and 2025 is 57.06%.
About Joseph Edelman and 13F Hedge Fund Stock Holdings
On 2026-05-29, the fund reported it's updated stock portfolio. In the 13F Holdings report, Joseph Edelman reported an equity portfolio of $5.1 Billions as of 31 Mar, 2026.
The top stock holdings of PERCEPTIVE ADVISORS LLC are PRAX, CELC, ASND. The fund has invested 12.8% of it's portfolio in PRAXIS PRECISION MEDICINES I and 7% of portfolio in CELCUITY INC.
The fund managers got completely rid off EXACT SCIENCES CORP (EXAS), ARCELLX INC (ACLX) and BOSTON SCIENTIFIC CORP (BSX) stocks. They significantly reduced their stock positions in NEUROCRINE BIOSCIENCES INC (NBIX), OMADA HEALTH INC and BELITE BIO INC (BLTE). PERCEPTIVE ADVISORS LLC opened new stock positions in IONIS PHARMACEUTICALS INC (IONS), DAY ONE BIOPHARMACEUTICALS I (DAWN) and DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to SAB BIOTHERAPEUTICS INC (SABS), RELAY THERAPEUTICS INC (RLAY) and CORVUS PHARMACEUTICALS INC (CRVS).
The top stock holdings of PERCEPTIVE ADVISORS LLC are PRAX, CELC, ASND. The fund has invested 12.8% of it's portfolio in PRAXIS PRECISION MEDICINES I and 7% of portfolio in CELCUITY INC.
The fund managers got completely rid off EXACT SCIENCES CORP (EXAS), ARCELLX INC (ACLX) and BOSTON SCIENTIFIC CORP (BSX) stocks. They significantly reduced their stock positions in NEUROCRINE BIOSCIENCES INC (NBIX), OMADA HEALTH INC and BELITE BIO INC (BLTE). PERCEPTIVE ADVISORS LLC opened new stock positions in IONIS PHARMACEUTICALS INC (IONS), DAY ONE BIOPHARMACEUTICALS I (DAWN) and DAMORA THERAPEUTICS INC (GLTO). The fund showed a lot of confidence in some stocks as they added substantially to SAB BIOTHERAPEUTICS INC (SABS), RELAY THERAPEUTICS INC (RLAY) and CORVUS PHARMACEUTICALS INC (CRVS).
Joseph Edelman Equity Portfolio Value
Last Reported on: 29 May, 2026
Joseph Edelman Annual Return Estimates Vs S&P 500
Our best estimate is that PERCEPTIVE ADVISORS LLC made a return of 4.73% in the last quarter. In trailing 12 months, it's portfolio return was 80.03%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| ionis pharmaceuticals inc | 37,845,400 |
| day one biopharmaceuticals i | 37,644,300 |
| damora therapeutics inc | 31,675,700 |
| revolution medicines inc | 25,148,800 |
| dbv technologies s a | 20,146,100 |
| sutro biopharma inc | 17,818,300 |
| evommune inc | 10,307,600 |
| phathom pharmaceuticals inc | 10,276,800 |
New stocks bought by PERCEPTIVE ADVISORS LLC
Additions
| Ticker | % Inc. |
|---|---|
| sab biotherapeutics inc | 700 |
| relay therapeutics inc | 412 |
| corvus pharmaceuticals inc | 231 |
| tenax therapeutics inc | 229 |
| biocryst pharmaceuticals inc | 135 |
| anteris technologies global | 104 |
| guardant health inc | 87.5 |
| centessa pharmaceuticals plc | 80.25 |
Additions to existing portfolio by PERCEPTIVE ADVISORS LLC
Reductions
| Ticker | % Reduced |
|---|---|
| neurocrine biosciences inc | -80.35 |
| omada health inc | -67.19 |
| belite bio inc | -63.31 |
| viridian therapeutics inc | -61.52 |
| opus genetics inc | -57.55 |
| inhibikase therapeutics inc | -57.3 |
| crescent biopharma inc. | -54.39 |
| adma biologics inc | -47.11 |
PERCEPTIVE ADVISORS LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| astria therapeutics inc | -84,894,100 |
| amicus therapeutics inc | -90,720,900 |
| aldeyra therapeutics inc | -21,681,600 |
| gossamer bio inc | -9,732,970 |
| savara inc | -14,472,000 |
| arcellx inc | -95,587,800 |
| exact sciences corp | -121,921,000 |
| caris life sciences inc | -30,654,800 |
PERCEPTIVE ADVISORS LLC got rid off the above stocks
Sector Distribution
PERCEPTIVE ADVISORS LLC has about 75.8% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 75.8 |
| Others | 23.7 |
Market Cap. Distribution
PERCEPTIVE ADVISORS LLC has about 7.9% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- SMALL-CAP
- LARGE-CAP
- MICRO-CAP
- NANO-CAP
| Category | % |
|---|---|
| MID-CAP | 48.2 |
| UNALLOCATED | 23.7 |
| SMALL-CAP | 15.3 |
| LARGE-CAP | 7.9 |
| MICRO-CAP | 3.7 |
| NANO-CAP | 1.1 |
Stocks belong to which Index?
About 42.5% of the stocks held by PERCEPTIVE ADVISORS LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 56.7 |
| RUSSELL 2000 | 42.5 |
Joseph Edelman Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Joseph Edelman
PERCEPTIVE ADVISORS LLC has 91 stocks in it's portfolio. About 51.4% of the portfolio is in top 10 stocks. RYTM proved to be the most loss making stock for the portfolio. AGLE was the most profitable stock for PERCEPTIVE ADVISORS LLC last quarter.
Last Reported on: 29 May, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACLX | arcellx inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ADGI | invivyd inc | 0.53 | 20,859,300 | 27,117,100 | reduced | -4.25 | ||
| ADMA | adma biologics inc | 0.08 | 467,233 | 4,209,770 | reduced | -47.11 | ||
| ADPT | adaptive biotechnologies cor | 0.04 | 152,500 | 2,116,700 | new | |||
| AGLE | spyre therapeutics inc | 3.73 | 3,783,220 | 190,826,000 | added | 23.26 | ||
| ALDX | aldeyra therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMLX | amylyx pharmaceuticals inc | 2.25 | 8,284,880 | 115,160,000 | unchanged | 0.00 | ||
| AORT | artivion inc | 1.17 | 1,637,290 | 59,957,600 | reduced | -4.94 | ||
| APLS | apellis pharmaceuticals inc | 0.06 | 80,956 | 3,256,860 | new | |||
| AQST | aquestive therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ASND | ascendis pharma a/s | 6.84 | 1,531,420 | 350,282,000 | added | 41.61 | ||
| ATHA | leonabio inc | 0.37 | 187,810 | 19,113,800 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTX | avalo therapeutics inc | 0.04 | 139,667 | 2,085,230 | unchanged | 0.00 | ||
| AXGN | axogen inc | 0.45 | 697,312 | 23,101,900 | reduced | -11.07 | ||
| AXSM | axsome therapeutics inc. | 0.50 | 149,950 | 25,344,500 | added | 0.71 | ||
| BCRX | biocryst pharmaceuticals inc | 1.38 | 7,434,030 | 70,772,000 | added | 135 | ||
| BDSX | biodesix | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BIIB | biogen inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BLTE | belite bio inc | 0.47 | 151,979 | 24,231,500 | reduced | -63.31 | ||